William Q. Sargent
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di William Q. Sargent
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 18 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a William Q. Sargent tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| MERCK & CO., INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Sales & Marketing Sales & Marketing | |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Biotechnology | Director of Finance/CFO | |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| TENGION, INC. | Biotechnology | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Director/Board Member Compliance Officer | |
Incline Therapeutics, Inc.
 Incline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Incline Therapeutics, Inc. develops pharmaceutical products. The firm operates as hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system). The company was founded in 2009 and is headquartered in Seatle, WA. | Pharmaceuticals: Major | Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| Dartmouth College | College/University | Undergraduate Degree | |
Broadpoint Securities, Inc.
 Broadpoint Securities, Inc. Investment Banks/BrokersFinance Part of Gleacher & Co., Inc., Broadpoint Securities, Inc. is a company that provides broker-dealer and investment banking services. The company is based in New York, NY. Broadpoint Securities was acquired by BroadPoint Securities Group, Inc. on May 17, 2004 for $32 million. | Investment Banks/Brokers | Corporate Officer/Principal | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree | |
| Yale University | College/University | Graduate Degree Corporate Officer/Principal | |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Pharmaceuticals: Major | Director of Finance/CFO | |
| CADENCE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder | |
BIOCOM
 BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | General Counsel Chairman Director/Board Member Director/Board Member Director/Board Member Director of Finance/CFO Director/Board Member Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Director/Board Member Public Communications Contact | |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
Life Sciences Pennsylvania
 Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Life Sciences Pennsylvania (LSPA) is a trade association that represents various entities in the life sciences industry, including biotechnology, medical device, diagnostic, pharmaceutical, research, and investment companies, as well as service providers. The non-profit company is based in Wayne, PA and has subsidiaries in the United States. The organization unifies innovators in the state to make Pennsylvania a leader in the life sciences industry. Founded in 1989, LSPA aims to create a business and public policy environment that encourages and incentivizes the diverse life sciences economy in Pennsylvania. Christopher P. Molineaux has been the CEO of the company since 2009. | Miscellaneous Commercial Services | Director/Board Member | |
| TREVENA, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Sharp Hospital Foundation | Director/Board Member | ||
| OTONOMY | Biotechnology | Director/Board Member Director/Board Member | |
Rempex Pharmaceuticals, Inc.
 Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Founder Director/Board Member | |
Nuron Biotech, Inc.
 Nuron Biotech, Inc. BiotechnologyHealth Technology Nuron Biotech, Inc. markets and develops vaccines for the prevention and treatment of infectious diseases. It develops novel biologics and vaccines for the prevention and treatment of neurodegenerative and infectious diseases. The firm is advancing products to meet unmet medical needs in the areas of multiple sclerosis, alzheimer's, hepatitis b and hepatitis c for patients across the globe. The company was founded by Vithalbhai Dhaduk, Shankar Musunuri and David Zeng in 2009 and is headquartered in Exton, PA. | Biotechnology | Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
| Yale School of Medicine | College/University | Corporate Officer/Principal Doctorate Degree | |
| SPARK THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| CIDARA THERAPEUTICS, INC. | Pharmaceuticals: Other | Chairman Director/Board Member | |
| VIKING THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| NEXTCURE, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Tripex Pharmaceuticals LLC
 Tripex Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Tripex Pharmaceuticals LLC provides pharmaceutical services. The company is headquartered in Encinas, CA. | Pharmaceuticals: Other | Chief Executive Officer Director/Board Member | |
Elucida Oncology, Inc.
 Elucida Oncology, Inc. BiotechnologyHealth Technology Elucida Oncology, Inc. operates as a biotechnology company which focuses on clinical research and development. The company was founded by Isaac Blech, Michelle Bradbury, Ulrich Weisner, and Steven Larson in 2014 and is headquartered in Monmouth Junction, NJ. | Biotechnology | Director/Board Member | |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Harmony Biosciences LLC
 Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | Pharmaceuticals: Major | Director/Board Member | |
Spark Therapeutics UK Ltd.
 Spark Therapeutics UK Ltd. Medical/Nursing ServicesHealth Services Part of Roche Holding AG, Spark Therapeutics UK Ltd. is a healthcare services provider. The company is based in London, UK. Spark Therapeutics was founded in 2016. | Medical/Nursing Services | Director/Board Member | |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Investment Managers | Consultant / Advisor | |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
OnCusp Therapeutics6
 OnCusp Therapeutics6 Miscellaneous Commercial ServicesCommercial Services OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then. | Miscellaneous Commercial Services | Director/Board Member | |
| SYNERGY PHARMACEUTICALS INC | Pharmaceuticals: Major | Director of Finance/CFO Human Resources Officer | |
| DURATA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 46 |
| Regno Unito | 4 |
| Canada | 2 |
| Austria | 2 |
Settori
| Health Technology | 34 |
| Commercial Services | 6 |
| Consumer Services | 6 |
| Finance | 5 |
| Distribution Services | 2 |
Posizioni
| Director/Board Member | 120 |
| Corporate Officer/Principal | 49 |
| Independent Dir/Board Member | 43 |
| Chief Tech/Sci/R&D Officer | 21 |
| Chairman | 19 |
Contatti più connessi
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| Mark Corrigan | 29 |
| Daniel Burgess | 28 |
| Axel Bolte | 23 |
| Stephen Webster | 23 |
| Theodore Schroeder | 16 |
| Gary Sender | 14 |
| Robert L. Crotty | 12 |
| John Naftzger | 12 |
| Elyse G. Seltzer | 11 |
| George Harrison Talbot | 10 |
| Jennifer Schranz | 10 |
| David Garrett | 9 |
| Francesco Maria Lavino | 7 |
| Steven Gelone | 7 |
- Borsa valori
- Insiders
- William Q. Sargent
- Connessioni Società
